Moderate to Severe Atopic Dermatitis Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06012812 -
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05549947 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT06136741 -
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT06099704 -
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
|
||
Completed |
NCT03568162 -
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00148746 -
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
|
N/A | |
Recruiting |
NCT05702268 -
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Not yet recruiting |
NCT06468956 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 3 | |
Not yet recruiting |
NCT05197023 -
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
|
Phase 1 | |
Recruiting |
NCT06239311 -
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
|
Phase 3 | |
Terminated |
NCT01286220 -
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
|
N/A | |
Completed |
NCT02426359 -
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
|
Phase 2 |